MedPath

Almaject, Inc.

Almaject, Inc. logo
🇺🇸United States
Ownership
Subsidiary
Established
2019-01-01
Employees
51
Market Cap
-
Website
http://www.almaject.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

16

FDA:16

Drug Approvals

Tranexamic Acid

Approval Date
Nov 28, 2023
FDA

Metoprolol Tartrate

Approval Date
Nov 27, 2023
FDA

Temsirolimus

Approval Date
Nov 15, 2023
FDA

Vancomycin Hydrochloride

Approval Date
Nov 14, 2023
FDA

Rocuronium Bromide

Approval Date
Nov 14, 2023
FDA

melphalan hydrochloride

Approval Date
Nov 8, 2023
FDA

Ketorolac Tromethamine

Approval Date
Nov 8, 2023
FDA

labetalol hydrochloride

Approval Date
Nov 8, 2023
FDA

ACETYLCYSTEINE

Approval Date
Nov 3, 2023
FDA

midazolam

Approval Date
Nov 1, 2022
FDA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.